Newsfile (Wed, 2-Sep 7:21 AM ET)
OS Therapies Reports Second Quarter 2026 Financials and Provides Business and Regulatory Updates
Newsfile (Mon, 17-Aug 7:40 AM ET)
Newsfile (Thu, 13-Aug 8:45 AM ET)
OS Therapies Accepts New FDA Meeting Request to Review Biomarker Data as Part of BEST Program
Newsfile (Wed, 8-Jul 9:02 AM ET)
OS Therapies Third Quarter 2026 Corporate Outlook
Newsfile (Mon, 6-Jul 9:01 AM ET)
OS Therapies Appoints Dr. Craig Eagle to Board of Directors
Newsfile (Thu, 2-Jul 7:33 AM ET)
OS Therapies Provides U.S. Regulatory Update
Newsfile (Tue, 30-Jun 7:41 AM ET)
Newsfile (Fri, 26-Jun 7:41 AM ET)
Newsfile (Mon, 8-Jun 6:02 AM ET)
EMA Rolling Review Marks Major Regulatory Milestone for OSTX’s Lead Osteosarcoma Therapy
Market Chameleon (Thu, 30-Apr 7:12 AM ET)
OS Therapies Inc is a clinical stage biopharmaceutical company focused on the identification, development and commercialization of treatments for Osteosarcoma (OS) and other solid tumors. The company's mission is to address the need for new treatments in cancers of the bone in children and young adults. The company has pipeline of product candidates targeting multiple indications for solid cancers including two drug technologies: (i) OST-HER2, an off-the-shelf immunotherapy, which is a type of cancer treatment that helps the immune system fight cancer and OST-tADC which is a tunable drug conjugate (tADC) platform currently in preclinical development. Each tADC contains four main components: ligand, payload cassette adaptor, linker and payload.
Os Therapies trades on the AMEX stock market under the symbol OSTX.
As of September 4, 2026, OSTX stock price climbed to $1.88 with 930,336 million shares trading.
OSTX has a beta of 1.31, meaning it tends to be more sensitive to market movements. OSTX has a correlation of 0.06 to the broad based SPY ETF.
OSTX has a market cap of $87.37 million. This is considered a Micro Cap stock.
Last quarter Os Therapies reported $0 in Revenue and -$.20 earnings per share. This fell short of revenue expectation by $-204,400 and exceeded earnings estimates by $.03.
The top ETF exchange traded funds that OSTX belongs to (by Net Assets): VTI, VXF, BUSM.
OSTX has underperformed the market in the last year with a return of -10.0%, while the SPY ETF gained +19.8%. In the last 3 month period, OSTX fell short of the market, returning +1.6%, while SPY returned +2.0%. However, in the most recent 2 weeks OSTX has outperformed the stock market by returning +18.2%, while SPY returned +0.6%.
OSTX support price is $1.75 and resistance is $1.89 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that OSTX shares will trade within this expected range on the day.
